Delayed culture conversion predicts poor outcomes for isoniazid mono-resistant TB in Uganda: a retrospective cross-sectional study from 2017– 2022
Abstract Background Isoniazid-resistant, Rifampicin-susceptible Tuberculosis (TB) is estimated to occur in 13% of new cases and 17% of previously treated cases. Current WHO guidelines recommend treatment with Rifampicin (RFP), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (LFX, Q) for...
Saved in:
| Main Authors: | Joel Kabugo, Obondo James Sande, Jupiter Marina Kabahita, Joanita Namutebi, Dennis Mujuni, Hellen Rosette Oundo, Daniel Kisakye, Dorothy Nassozi Batte, Moses Joloba, Gerald Mboowa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-025-11218-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Isoniazid - induced chronic cutaneous Lupus erythematosus
by: A Chiriac, et al.
Published: (2016-01-01) -
Isoniazid - induced chronic cutaneous Lupus erythematosus
by: A Chiriac, et al.
Published: (2016-01-01) -
Effect of isoniazid and its compositions with oxidized dextran on the activity of inflammation and destruction processes in the liver of mice with BCG granulomatosis
by: A. M. Sinyavskaya, et al.
Published: (2025-07-01) -
Analysis of Isoniazid, Streptomycin and Ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco
by: Imane Chaoui, et al.
Published: (2009-05-01) -
New Complexes of Isoniazid Derivative with 3d Metals: Synthesis, Structure and Molecular Docking
by: M. A. Ahmed, et al.
Published: (2023-11-01)